Kaerus Bioscience, a biotechnology company dedicated to translating scientific advances into treatments for patients with rare genetic neurodevelopmental syndromes, has announced a technology access partnership with Neurolentech. Neurolentech is a startup focused on drug discovery for epilepsy and genetic neurodevelopmental disorders (NDDs), and through this agreement, Kaerus Bioscience will be able to utilize Neurolentech’s NDD Drug Discovery platform.
Neurolentech’s Platform is specifically designed for NDD drug discovery, allowing for the modeling of neural networks associated with genetic NDDs at a cellular level. This will enable Kaerus Bioscience to explore the therapeutic potential of its small molecule pipeline for a range of genetic syndromes in preclinical studies. By leveraging these cell models and assays, Kaerus Bioscience aims to drive progress in research on neurodevelopmental disorders.
The partnership signifies a significant step for Neurolentech in its mission to advance drug discovery for NDDs. It also solidifies the company’s NDD Drug Discovery platform as a valuable resource for researchers and industry partners looking to develop new therapies for these disorders. Fiona Nielsen, CEO of Neurolentech, expressed enthusiasm about the collaboration with Kaerus Bioscience and the opportunities it presents for advancing research in neurodevelopmental disorders. Robert Ring, CEO of Kaerus Bioscience, highlighted the company’s dedication to using innovative technologies to accelerate the discovery of treatments for patients with genetic neurodevelopmental disorders.
